Patients considering maintenance lurbinectedin with atezolizumab need comprehensive information about potential adverse effects to make informed treatment decisions with their hea ...

(RTTNews) - X4 Pharmaceuticals, Inc. (XFOR), Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia ...